Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;68(6):e28982.
doi: 10.1002/pbc.28982. Epub 2021 Mar 9.

Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?

Charlotte Rigaud  1 , Rachid Abbas  2 , David Grand  3 , Véronique Minard-Colin  1 , Nathalie Aladjidi  4 , Nimrod Buchbinder  5 , Nathalie Garnier  6 , Geneviève Plat  7 , Marie-Laure Couec  8 , Mylène Duplan  9 , Anne Lambilliotte  10 , Claudine Schmitt  11 , Thierry Leblanc  12 , Laurence Lamant  3 , Laurence Brugières  1
Affiliations

Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?

Charlotte Rigaud et al. Pediatr Blood Cancer. 2021 Jun.

Abstract

In anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALK+ ALCL), positive minimal residual disease (MRD+) after the first chemotherapy course was proven of strong prognostic significance. We aimed to validate these results in 138 French patients. Eighty-seven patients had a detectable minimal disseminated disease at diagnosis (MDD+). Early MRD assessment was performed in 33 of 87 patients and was positive in 18 and negative in 15 (MRD-). Three-year progression-free survival was significantly correlated with the MDD/MRD status: 81.1% in MDD-, 69.6% in MDD+/MRD-, and 15.2% in MDD+/MRD+ patients. In conclusion, we confirmed on an independent cohort that the MDD/MRD status has strong prognosis significance in ALK+ ALCL.

Keywords: ALCL; MRD; anaplastic large cell lymphoma; minimal residual disease.

PubMed Disclaimer

References

REFERENCES

    1. Lamant L, Meggetto F, al Saati T, et al. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood. 1996;87(1):284-291.
    1. Damm-Welk C, Klapper W, Oschlies I, et al. Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation. Br J Haematol. 2009;146(3):306-309.
    1. Le Deley M-C, Reiter A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008;111(3):1560-1566.
    1. Lamant L, McCarthy K, d'Amore E, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(35):4669-4676.
    1. Damm-Welk C, Mussolin L, Zimmermann M, et al. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2014;123(3):334-337.

MeSH terms

Substances

LinkOut - more resources